Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

Lancet

Volumn 362, Issue 9391, 2003, Pages 1184-1191

  Sorensen, Per Soelberg ^a   Ross, Christian ^a   Clemmesen, Katja Maria ^a   Bendtzen, Klaus ^a   Frederiksen, Jette Lautrup ^b   Jensen, Kai ^c   Kristensen, Ole ^d   Petersen, Thor ^e   Rasmussen, Soren ^h   Ravnborg, Mads ^a   Stenager, Egon ^f   Koch Henriksen, Nils ^g  

^a Rigshospitalet   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f University of Esbjerg   (Denmark)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON;

ADULT; ANTIBODY DETECTION; ARTICLE; BIOASSAY; CONTROLLED STUDY; DISEASE COURSE; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RATING SCALE; RECURRENT DISEASE; RELAPSE; REMISSION; SEX DIFFERENCE; VIRUS NEUTRALIZATION;

EID: 10744225329     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14541-2     Document Type: Article

References (30)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;655-661.
2. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 45:1995;1277-1285.
3. Paty D.W., Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;662-667.
4. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 39:1996;285-294.
5. Rudick R.A., Goodkin D.E., Jacobs L.D., et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology. 49:1997;358-363.
6. Simon J.H., Jacobs L.D., Campion M., et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol. 43:1998;79-87.
7. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 352:1998;1498-1504.
8. Miller D.H., Molyneux P.D., Barker G.J., MacManus D.G., Moseley I.F., Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol. 46:1999;850-859.
9. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 352:1998;1491-1497.
10. Li D.K., Paty D.W. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol. 46:1999;197-206.
11. Abdul Ahad A.K., Galazka A.R., Revel M., Biffoni M., Borden E.C. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Cytokines Cell Mol Ther. 3:1997;27-32.
12. Rudick R.A., Simonian N.A., Alam J.A., et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology. 50:1998;1266-1272.
13. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology. 47:1996;889-894.
14. Ross C., Clemmesen K.M., Svenson M., et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol. 48:2000;706-712.
15. Koch-Henriksen N., Sorensen P.S. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. Mult Scler. 6:2000;172-175.
16. Schumacher G.A., Beebe G., Kibler R.F., et al. Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 122:1965;552-568.
17. Hansen M.B., Ross C., Berg K. A sensitive antiviral neutralization bioassay for measuring antibodies to interferons. J Immunol Methods. 127:1990;241-248.
18. Ross C., Svenson M., Hansen M.B., Vejlsgaard, Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest. 95:1995;1974-1978.
19. Kivisakk P., Alm G.V., Fredrikson S., Link H. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol. 7:2000;27-34.
20. Cook S.D., Quinless J.R., Jotkowitz A., Beaton P. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology. 57:2001;1080-1084.
21. Bertolotto A., Malucchi S., Milano E., Castello A., Capobianco M., Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology. 48:2000;95-100.
22. Bertolotto A., Malucchi S., Sala A., et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry. 73:2002;148-153.
23. Antonelli G., Bagnato F., Pozzilli C., et al. Development ofneutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J Interferon Cytokine Res. 18:1998;345-350.
24. Oger J.J.F., Vorobeychick G., Al-Fahim A., Aziz T., Edan G., Paty D. Neutralizing antibodies in betaseron-treated MS patients and in vitro immune function before treatment. Neurology. 48:1997;A80.
25. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 56:2001;1628-1636.
26. Pachner A.R. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurology. 49:1997;647-650.
27. Deisenhammer F., Reindl M., Harvey J., Gasse T., Dilitz E., Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology. 52:1999;1239-1243.
28. Kracke A., von Wussow P., Al Masri A.N., Dalley G., Windhagen A., Heidenreich F. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology. 54:2000;193-199.
29. Rice G.P., Paszner B., Oger J., Lesaux J., Paty D., Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology. 52:1999;1277-1279.
30. Khan O.A., Dhib-Jalbut S.S. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology. 51:1998;1698-1702.